We are live on ! Find out more
ESLA icon

Estrella Immunopharma
ESLA

11 hedge funds and large institutions have $341K invested in Estrella Immunopharma in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

47% more capital invested

Capital invested by funds: $232K → $341K (+$109K)

10% more funds holding

Funds holding: 10 → 11 (+1)

0.26% more ownership

Funds ownership: 0.55% → 0.81% (+0.26%)

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$59.1K
2
State Street
State Street
Massachusetts
+$22.5K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$17K
4
TSS
Two Sigma Securities
New York
+$10.7K
5
BlackRock
BlackRock
New York
+$156

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$16.9K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.96K
3
JP Morgan Chase
JP Morgan Chase
New York
-$1

ESLA Hedge Fund Activity: Q4 2024 in Review

11 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q4 2024, worth a combined $341K — up 47% from $232K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ESLA positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.

The largest buyer was UBS Group, adding an estimated $59.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $16.9K sold.

  • 11 institutional investors held Estrella Immunopharma (ESLA) as of Q4 2024, up from 10 in Q3 2024.
  • Funds reported $341K of Estrella Immunopharma stock for Q4 2024, up 47% quarter-over-quarter.
  • 2 funds opened new Estrella Immunopharma positions in Q4 2024 and 1 closed out, a net change of +1 holder.
  • The largest Estrella Immunopharma buyer in Q4 2024 was UBS Group, an estimated $59.1K added.
  • The largest Estrella Immunopharma seller in Q4 2024 was Citadel Advisors, an estimated $16.9K sold.

Based on aggregated 13F filings for Q4 2024.